Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142,445 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tuberculosis in hematopoietic stem cell transplant recipients in Korea.
Lee J, Lee MH, Kim WS, Kim K, Park SH, Lee SH, Lee KE, Park J, Park JO, Jung CW, Im YH, Kang WK, Park K. Lee J, et al. Among authors: lee sh, lee mh, lee ke. Int J Hematol. 2004 Feb;79(2):185-8. doi: 10.1532/ijh97.a10219. Int J Hematol. 2004. PMID: 15005349
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular carcinoma.
Lee J, Park JO, Kim WS, Park SH, Park KW, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC, Joh J, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K. Lee J, et al. Among authors: lee mh, lee jh. Cancer Chemother Pharmacol. 2004 Nov;54(5):385-90. doi: 10.1007/s00280-004-0837-7. Epub 2004 Jul 10. Cancer Chemother Pharmacol. 2004. PMID: 15248028 Clinical Trial.
Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer.
Park SH, Lee J, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Park YS, Kang WK, Park K, Kim S, Bang SM, Cho EK, Shin DB, Lee JH. Park SH, et al. Among authors: lee sh, lee j, lee jh. Cancer Chemother Pharmacol. 2006 Jan;57(1):91-6. doi: 10.1007/s00280-005-0027-2. Epub 2005 Nov 5. Cancer Chemother Pharmacol. 2006. PMID: 16088407
Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer.
Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY, Kang WK. Yi SY, et al. Among authors: lee kt, lee j, lee jk. Cancer Chemother Pharmacol. 2009 May;63(6):1141-5. doi: 10.1007/s00280-008-0839-y. Epub 2008 Oct 7. Cancer Chemother Pharmacol. 2009. PMID: 18839175 Clinical Trial.
142,445 results
You have reached the last available page of results. Please see the User Guide for more information.